← Back to Search

Riociguat for Sarcoidosis (RioSAPH Trial)

Phase 4
Waitlist Available
Led By Robert P Baughman, MD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights

RioSAPH Trial Summary

Double blind placebo controlled trial of riociguat for sarcoidosis associated pulmonary hypertension

Eligible Conditions
  • Sarcoidosis

RioSAPH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time until clinical worsening
Secondary outcome measures
Pulmonary function
Quality of life
Safety: adverse events
+1 more

RioSAPH Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: RiociguatActive Control1 Intervention
Active drug
Group II: PlaceboPlacebo Group1 Intervention
placebo

Find a Location

Who is running the clinical trial?

University of CincinnatiLead Sponsor
430 Previous Clinical Trials
634,431 Total Patients Enrolled
14 Trials studying Sarcoidosis
3,712 Patients Enrolled for Sarcoidosis
Robert P Baughman, MDPrincipal InvestigatorUniversity of Cincinnati
10 Previous Clinical Trials
2,530 Total Patients Enrolled
9 Trials studying Sarcoidosis
2,515 Patients Enrolled for Sarcoidosis
Steve Nathan, MDPrincipal InvestigatorInova Fairfax Hospital
~6 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top